Critics question antitrust agencies’ increasing reliance on monitors


When the Federal Trade Commission allowed pharmaceutical behemoth Teva to acquire Allergan’s generic business, conditioned on relinquishing 79 of its generic drugs — the largest drug divestiture in one of the commission’s cases — the agency had a backstop to make sure the deal went off without a hitch.

The FTC